 "Drug firms, Lupin, Cadila Healthcare")
Cadila Healthcare reported a subdued showing for the March 2020 quarter (Q4), partly on account of last year’s high base and the Covid-led supply disruptions.
Yet, investor confidence remains firm, reflected in its stock that continues to trade near 52-week highs. The key factor is the drug major’s strong outlook.
Revenues in Q4 came in flat. While domestic sales — which contribute about a fourth to overall revenue — were also little changed, US sales (47 per cent of the top line) declined by 1.2 per cent year-on-year (YoY).
Sales in emerging markets and Latam were also weak, as supply
